Cancer patients urge rethink over treatment

Six years ago Abiraterone was hailed as a medical breakthrough that could offer men extra time with loved ones and a chance to delay chemotherapy and its debilitating side effects. But today the body that recommends what can and cant be paid for said it 'wasn't cost effective'.

View all 2 updates ›

Lincolnshire cancer patient: don't take drug away

The body that recommends what drugs can and cannot be paid for now says a drug once hailed as a breakthrough is not "cost effective".

A man from Lincolnshire who won his fight against prostate cancer has joined the ranks of those calling for Arbiraterone to remain available:

More top news